Angiogenic effects of combined gene therapeutic construction pcDNA_VEGF165/Ang-1 in conditions of modeling chronic limb ischemia in vivo

The combined plasmid construct pcDNA_VEGF165/Ang-1 has a pronounced angiogenic effect under the conditions of the modeled experimental chronic insufficiency of arterial blood supply to the limb. A single local administration of pcDNA_VEGF165/Ang-1 at a dose of 100 μg into the ischemic skeletal muscle of laboratory animals starting from the 14th day after therapy stimulates the formation of microcirculatory bed vessels with a statistically significant increase in the number of capillaries. The use of the gene therapeutic substance pcDNA_VEGF165/Ang-1 allows for complete restoration of impaired blood supply in the muscles of the thigh and lower leg of the rats by the 28th day of observation, creates conditions for maintaining a long-term positive effect until the end of the experiment (42nd day) while maintaining the number of blood vessels in one muscle fiber not lower than the healthy tissue indicator.